Pancreas News and Research

RSS

The pancreas is a gland organ in the digestive and endocrine system of vertebrates. It is both an endocrine gland producing several important hormones, including insulin, glucagon, and somatostatin, as well as an exocrine gland, secreting pancreatic juice containing digestive enzymes that pass to the small intestine. These enzymes help in the further breakdown of the carbohydrates, protein, and fat in the chyme.

Experts to focus on Shwachman-Diamond Syndrome at New York Academy of Sciences conference

On June 28-30, 2011, the New York Academy of Sciences will bring together scientists and clinicians from a wide range of subspecialties, in addition to patients and caregivers, to discuss the most important recent advances in our understanding of the clinical features, management, and treatment of Shwachman-Diamond Syndrome (SDS)-a rare disorder involving multiple organ systems and affecting children and young adults.

23 Jun 2011

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced today that the European Commission has granted marketing authorization to BYDUREON.

21 Jun 2011

FDA's draft guidance document addresses artificial pancreas system for type 1 diabetes

The U.S. Food and Drug Administration today issued draft guidance that will help advance the development and approval of an artificial pancreas system to treat type 1 diabetes in the United States.

21 Jun 2011

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA injection and SYMLIN injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28.

21 Jun 2011

NIH-funded study to develop virtual reality simulator for 'scarless' endoscopic surgery

Researchers at Rensselaer Polytechnic Institute have secured a $2.7 million grant to develop the first-ever virtual reality simulator for next-generation "scarless" endoscopic surgery.

20 Jun 2011

Cedars-Sinai receives National Eye Institute grant to develop gene therapy for corneal disease

Cedars-Sinai stem cell researchers investigating ways to prevent eye problems in diabetic patients have been awarded a $3 million grant from the National Eye Institute to develop gene therapy in corneal stem cells to alleviate damage to corneas that can cause vision loss.

17 Jun 2011

Liver stiffness measurement could replace liver biopsy for evaluation of hepatitis C

Non-invasive tests for liver fibrosis, such as liver stiffness measurement or the FibroTest, can predict survival of patients with chronic hepatitis C, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

15 Jun 2011

FDA approves Abbott's CREON capsules for treatment of EPI due to cystic fibrosis

Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON Delayed-Release Capsules to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis.

15 Jun 2011

Abbott’s CREON receives FDA approval for infant-specific dose

Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON® (pancrelipase) Delayed-Release Capsules to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF). The CREON 3,000 units of lipase capsule provides the lowest dosage strength in the class approved by the FDA. This new option will enable more precise dosing titration in accordance with the Cystic Fibrosis Foundation guidelines for infant dosing.

14 Jun 2011

Poor maternal nutrition predisposes offspring to type 2 diabetes

A new study published by the American Physiological Society offers the strongest evidence yet that vulnerability to type 2 diabetes can begin in the womb, giving new insight into the mechanisms that underlie a potentially devastating disease at the center of a worldwide epidemic.

14 Jun 2011

Nose spray vaccine for type 1 diabetes could be a reality soon

Melbourne researchers are nearing the development of a vaccine for type 1 diabetes, after showing that a nasal spray can stop the body's immune system from attacking insulin-producing cells.

13 Jun 2011

Only 35% of anaesthesiologists carry out cardiac output monitoring during high-risk surgery

Only 35% of anaesthesiologists are carrying out a simple procedure during high-risk surgery that can make a significant impact on how well patients recover from their operations, according to new research presented today at the European Anaesthesiology Congress in Amsterdam.

13 Jun 2011

Promising new strategy for treating human type 2 diabetes

In a mouse study, scientists at Mayo Clinic Florida have demonstrated the feasibility of a promising new strategy for treating human type 2 diabetes, which affects more than 200 million people worldwide.

10 Jun 2011

Promising new strategy for treating human type 2 diabetes

10 Jun 2011

Amylin disappointed with U.S. District Court's ruling in BYETTA preliminary injunction

Amylin Pharmaceuticals, Inc. today issued the following statement regarding the decision of the United States District Court for the Southern District of California to deny its motion for a preliminary injunction to enjoin Eli Lilly and Company from engaging in anticompetitive activity and breaching its diabetes collaboration agreement with Amylin.

10 Jun 2011

Simple urine test could detect early stage cancers

Cancers of the gut, stomach and pancreas could be detected much sooner with a simple urine test, research suggests.

10 Jun 2011

Accuray receives shareholders approval to acquire TomoTherapy

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that TomoTherapy shareholders have approved the proposed acquisition of TomoTherapy Incorporated by Accuray.

10 Jun 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen Corporation today reported results for the fourth quarter and fiscal year 2011, ended March 31, 2011.

9 Jun 2011

JDRF, Selecta Biosciences partner to develop type 1 diabetes vaccine

The Juvenile Diabetes Research Foundation (JDRF) and Selecta Biosciences, Inc. announced today that they have established a research collaboration to support Selecta's development of a vaccine technology, which may subsequently help to better treat and potentially prevent type 1 diabetes.

9 Jun 2011

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that Seattle Genetics has exercised an option to co-develop a second antibody-drug conjugate (ADC) under the companies' existing ADC collaboration agreement.

9 Jun 2011

Pancreas News and Research

Further Reading

Experts to focus on Shwachman-Diamond Syndrome at New York Academy of Sciences conference

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

FDA's draft guidance document addresses artificial pancreas system for type 1 diabetes

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

NIH-funded study to develop virtual reality simulator for 'scarless' endoscopic surgery

Cedars-Sinai receives National Eye Institute grant to develop gene therapy for corneal disease

Liver stiffness measurement could replace liver biopsy for evaluation of hepatitis C

FDA approves Abbott's CREON capsules for treatment of EPI due to cystic fibrosis

Abbott’s CREON receives FDA approval for infant-specific dose

Poor maternal nutrition predisposes offspring to type 2 diabetes

Nose spray vaccine for type 1 diabetes could be a reality soon

Only 35% of anaesthesiologists carry out cardiac output monitoring during high-risk surgery

Promising new strategy for treating human type 2 diabetes

Promising new strategy for treating human type 2 diabetes

Amylin disappointed with U.S. District Court's ruling in BYETTA preliminary injunction

Simple urine test could detect early stage cancers

Accuray receives shareholders approval to acquire TomoTherapy

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

JDRF, Selecta Biosciences partner to develop type 1 diabetes vaccine

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News